Fudan University clinical trial pipeline
Data updated daily from ClinicalTrials.gov, last refresh 2026-11-19
What changed in the last 30 days
18 trials changed in the last 30 days: 0 stopped, 7 with notable changes, 11 with minor changes only.
- Notable: CASTLE-ZS-04 · Cryoablation Combined With QL1706 (Iparomlimab/Tuvonralimab) Plus Lenvatinib · Advanced Biliary Tract Cancer Recruitment opened
-
Minor: 6 trials marked Unknown by the registry's verification sweep Changed
- Minor: Ascorbic Acid and Adebrelimab in Metastatic Colorectal Cancer Changed Registry marked status Unknown (sponsor has not verified the record since Oct 2024); last known: Recruiting
- Minor: Lvosidenib (AK112) Combined With CapeOX and Radiotherapy · Unresectable Metastatic MSS-type Colorectal Cancer Changed Registry marked status Unknown (sponsor has not verified the record since Sep 2024); last known: Not Yet Recruiting
- Minor: Vaccine Chatbot for Improving Influenza Vaccination Uptake Changed Registry marked status Unknown (sponsor has not verified the record since Oct 2024); last known: Not Yet Recruiting
- Minor: AiRE-MS · AI-based Skeleton Recognition System for Rehabilitation Exercise in Breast Cancer Survivors: A Randomized Controlled Trial Changed Registry marked status Unknown (sponsor has not verified the record since Oct 2024); last known: Recruiting
- Minor: Multimodal Thermal Therapy · Early-stage Invasive Breast Cancer Changed Registry marked status Unknown (sponsor has not verified the record since Oct 2024); last known: Not Yet Recruiting
- Minor: Rechallenge of ADCs in MBC Patients Changed Registry marked status Unknown (sponsor has not verified the record since Oct 2024); last known: Active, Not Recruiting
- Notable: BALISTA · BrAin Metastasis in tripLe Negateive Breast Cancer: IvoneScimab and Trop2 ADC Primary completion pushed from Jan 31, 2026 to Dec 31, 2026
- Notable: BCTOP-T-N01 · Camrelizumab Plus Chemotherapy in Combination With or Without Famitinib as Neoadjuvant Therapy · Triple Negative Breast Cancer Primary completion date changed from estimate of Aug 30, 2025 to May 30, 2026
- Notable: EXPLORE · ReaL World Study of DS-8201 Primary completion date changed from estimate of Jun 30, 2025 to Apr 1, 2026
- Notable: SPECTACLE · Paclitaxel Polymeric Micelles Combined With HP and Adebelimab Versus Taxane Combined With HP as First-Line Treatment for Advanced HER2-Positive Breast Cancer Recruitment opened
- Notable: PROTECT · Prophylactic RespOnse To hEtrombopag for Secondary Prevention in Anti-Cancer Therapy-induced Thrombocytopeniae Recruitment opened
- Minor: Real World Study of Sacituzumab Govitecan Primary completion pushed from Aug 1, 2026 to Dec 1, 2026
- Notable: Family Physician Nudges for Influenza Vaccination Among Older Adults Enrollment reduced: 5250 → 3060 participants
- Minor: INOVATE · Intrathecal/Ommaya T-DXd in HER2-Expressing Breast Cancer With Leptomeningeal/Brain Metastases Primary completion pushed from Aug 30, 2026 to Jan 30, 2027
- Minor: Gonadotropin-releasing Hormone Agonist (GnRHa) Plus Letrozole In Young · Early Endometrial Cancer Enrollment closed, study ongoing
- Minor: Renaissance · Reverse Triple Negative Immune Resistant Breast Cancer Enrollment increased: 80 → 90 participants
- Minor: G-CSF Combined With IL-11 on Hematopoietic Reconstitution After Autologous Hematopoietic Stem Cell Transplantation Trial sites expanded: 3 → 7 locations
- Stopped: terminated, suspended or withdrawn
- Notable: the plan changed
- Minor: routine updates
New trial filings, last 30 days
| First posted | Trial | Phase | Status |
|---|---|---|---|
| 2026-11-18 | NCT07945353 Orelabrutinib Plus 4 Gy Radiotherapy Versus 24 Gy Radiotherapy for Stage I/II MALT… | Phase 2 | Not Yet Recruiting |
| 2026-11-16 | NCT07939009 Knife Movement Rate Training for Endoscopic Submucosal Dissection: A Randomized Study | Not Yet Recruiting | |
| 2026-11-13 | NCT07934745 Radiotherapy Plus Putelimab and Vibostolimab for Advanced Anal Squamous Cell Carcinoma | Phase 2 | Not Yet Recruiting |
| 2026-11-12 | NCT07933679 SCRT Combined With CAPOX and PD-1 Antibody Versus LCRT Combined With CAPOX for Early… | Phase 3 | Not Yet Recruiting |
| 2026-11-10 | NCT07928427 Comparing Ultrafractionated and Moderate Hypofractionated Radiotherapy for Post-Surgery… | Phase 3 | Active, Not Recruiting |
| 2026-11-06 | NCT07920731 A Single-Arm Study of Nimotuzumab Combined With NALIRIFOX as First-Line Treatment for… | Phase 2 | Enrolling by Invitation |
| 2026-11-06 | NCT07923812 Effectiveness and Safety of Disease-Modifying Therapy for Alzheimer's Disease: A… | Recruiting | |
| 2026-11-05 | NCT07918079 Netupitant/Palonosetron for Prevention of Nausea and Vomiting in Breast Cancer ADC Therapy | Phase 2 | Not Yet Recruiting |
| 2026-11-04 | NCT07917104 Circulating Tumor DNA Methylation-Guided Adjuvant Therapy Decision-Making in Patients… | Phase 2 | Recruiting |
| 2026-11-03 | NCT07912710 China HEalthy Aging and Dementia Study (HEAD) | Recruiting |
Active trials by phase
| Early Phase 1 | 4 | |
| Phase 1 | 4 | |
| Phase 1/2 | 18 | |
| Phase 2 | 257 | |
| Phase 2/3 | 7 | |
| Phase 3 | 78 | |
| Phase 4 | 14 |
Not charted: 189 active trials with no phase listed on ClinicalTrials.gov (typically behavioural, device, procedure and observational studies).
Disease areas by active trials, top 10 of 35
Breast Cancer (141) · Colorectal Cancer (87) · Lung Cancer (46) · Non-Small Cell Lung Cancer (NSCLC) (36) · Triple-Negative Breast Cancer (36) · Gastric Cancer (33) · Head & Neck Cancer (29) · Pancreatic Cancer (27) · Esophageal Cancer (22) · Liver Cancer (17)
Get alerts when Fudan University's trials change
Status changes, date slips, and new filings: detected daily, delivered to your inbox.